Advanced or metastatic squamous cell carcinoma of the esophagus research hub

A 3-Arm, Randomized, Blinded, Active-Controlled, Phase II Study of RO7121661, a PD1-TIM3 Bispecific Antibody and RO7247669, a PD1-LAG3 Bispecific Antibody, Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

This study compares new combination treatments (RO7121661 and RO7247669) against a standard treatment (Nivolumab) for advanced oesophageal cancer. Researchers want to see if the new treatments help people live longer and if they are safe.